Tumor and Flu Virus: Two Birds With One Drug

Scientists have found that a drug, called DMXAA, originally developed as anti-tumor agent, also enhances the ability of flu vaccines to ward off this deadly virus.

Their study suggests that DMXAA could assist flu vaccines by causing the body to produce its own antiviral proteins, called interferons, which interfere with the virus's ability to spread.

About Brain Tumor
Brain tumors are the abnormal growth of brain cells that may be benign or metastatic. Brain tumors account for about 2.4% of all the tumor diagnosesandare most challenging due to their critically delicate location.

In addition, DMXAA may be a useful antiviral therapy to treat newly emerging strains of the flu for which a vaccine has not been developed.

"We are hopeful that DMXAA or similar agents can be used ultimately to blunt the impact of yearly influenza outbreaks, and perhaps, for other virus infections as well," said Stefanie Vogel at the University of Maryland, co-author of the study.

In the study, Vogel and colleagues infected mice with a mouse-adapted influenza strain.

Carcinoid Tumors - Carcinoid Syndrome - Symptoms, Signs, Diagnosis & Treatment
Carcinoid tumors is a benign tumor that results in carcinoid syndrome. Only 8 to 10% of all carcinoid tumors are associated with the carcinoid syndrome.

When given DMXAA three hours before or after infection and then two days later, the infection was significantly less severe.

In addition, they found that DMXAA protected cells from flu strains that are resistant to Tamiflu, one of the most advanced anti-flu drugs on the market.

Tumor Markers - For Cancer Diagnosis and Prognosis
An ideal tumor marker for a cancer should be specific to that cancer and not generate false positive results.

These discoveries suggest that DMXAA could potentially enhance the efficacy of current flu treatments and vaccines, and perhaps treat other viruses or bacteria.

To be sure that DMXAA led to increased production of interferons, the researchers also tested it in mice that lacked a gene needed to produce interferon, and found that these mice received no benefit from DMXAA.

New, Effective Platinum-based Anti-tumour Drugs Developed
Scientists have developed a new class of platinum-based anti-tumour drugs that animal studies have shown to be 10 times more effective than current treatments in destroying certain

The study was published in the March 2011 issue of the Journal of Leukocyte Biology.

Source-ANI